Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chubb Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Chubb Ltd trades at $350.16 (market cap $134.91B). The key difference: Chubb Ltd is far larger — about 3.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Chubb Ltd pays a 1.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CB | |
|---|---|---|
Market Cap | $39.89B | $134.91B |
Sector | Health | Financials |
52-Week High | $491.22 | $361.17 |
52-Week Low | $278.09 | $265.99 |
Enterprise Value | $38.15B | $155.96B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Chubb Limited (CB) trades at $347.83, showing minimal daily movement with a slight 0.01% gain. The stock exhibits bullish technical signals from moving averages and strong fundamental health, including consistent earnings beats and a net income margin of 18.46%. Recent news highlights disciplined capital deployment and premium growth, while the upcoming Q2 2026 earnings report on July 22, 2026, is highly anticipated.
The outlook remains positive given analyst consensus favoring Buy ratings and a price target of $354.69, suggesting modest upside. Key risks include catastrophe losses and softer commercial pricing, but the company's robust balance sheet and rising investment income support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
